CA2540147A1 - Colon cleansing composition and method - Google Patents
Colon cleansing composition and method Download PDFInfo
- Publication number
- CA2540147A1 CA2540147A1 CA002540147A CA2540147A CA2540147A1 CA 2540147 A1 CA2540147 A1 CA 2540147A1 CA 002540147 A CA002540147 A CA 002540147A CA 2540147 A CA2540147 A CA 2540147A CA 2540147 A1 CA2540147 A1 CA 2540147A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- combination
- bisacodyl
- sodium
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Abstract
A composition and method for cleansing a colon prior to endoscopic procedure.
More particularly, a combination of bisacodyl, metoclopramide, sodium, and/or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.
More particularly, a combination of bisacodyl, metoclopramide, sodium, and/or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.
Description
COLON CLEANSING COMPOSITION AND METHOD
FIELD OF INVENTION
This invention relates to a composition and method for preparing a colon for an endoscopic procedure. More particularly, this invention relates to a composition and method for cleansing a colon prior to colonoscopy.
BACKGROUND OF INVENTION
Colonoscopy is an endoscopic procedure designed for detecting cancers or polyps of the colon at early stages so.
that identified cancers can be timely and effectively treated. It is known, for example, that when certain cancers are detected at an early stage, survivability statistics are at their highest.
In order to perform a colonoscopy, a colonoscope is used. A conventional colonoscope, as has been employed in the medical arts for many years, is constructed of a flexible tube containing fiber optics and a miniature CCD
(or other type) camera and light located at the tube's distal end. A small lens is employed at the tube end in order to focus light onto the camera.
During a colonoscopy procedure, the distal end of a colonoscope is inserted into the colon and images of the interior walls of the colon are transmitted to a video screen. In this manner, abnormalities in the colon may be observed and, in certain instances, polyps identified and removed such as for biopsy. Because it is extremely important that the view of the colon walls not be impeded by waste matter, and because the size of the lens of the colonoscope is very small and therefore easily obstructed, it is critical to performing a successful colonoscopy that the colon be thoroughly cleansed prior to the procedure.
For the foregoing reasons, various colon preparation compositions and methods have been employed in the past for cleansing or purging the colon prior to endoscopy. Although many of these compositions and/or methods achieve their intended purpose, known colon preparation procedures are inconvenient and/or uncomfortable to the patient to which they are administered.' For example, a commonly used colon preparation composition is manufactured and sold under the tradename Fleet Phospho-Soda ~M (hereinafter FleetTM) . In order to achieve the desired result using FleetTM (sufficient cleansing of the colon), a patient must typically ingest approximately 80 ounces or more of fluids over a relatively short interval of time the day or evening prior to the colonoscopy procedure. Because the ingestion of large volumes of fluid can cause discomfort and, in some instances, nausea or other undesirable symptoms, alternative means to cleanse a colon prior to endoscopy are desired.
In view of the above-enumerated drawbacks, it is apparent that there exists a need in the art for compositions and/or methods for pre-colonoscopy colon preparation which overcome the above drawbacks. It is a purpose of this invention to fulfill these needs in the art, as well as other needs which will become apparent to the skilled artisan once given the above disclosure.
SUMMARY OF INVENTION
Generally speaking, this invention fulfills the above described needs in the art by providing:
a method of cleansing a colon in preparation for a colonoscopy comprising:
FIELD OF INVENTION
This invention relates to a composition and method for preparing a colon for an endoscopic procedure. More particularly, this invention relates to a composition and method for cleansing a colon prior to colonoscopy.
BACKGROUND OF INVENTION
Colonoscopy is an endoscopic procedure designed for detecting cancers or polyps of the colon at early stages so.
that identified cancers can be timely and effectively treated. It is known, for example, that when certain cancers are detected at an early stage, survivability statistics are at their highest.
In order to perform a colonoscopy, a colonoscope is used. A conventional colonoscope, as has been employed in the medical arts for many years, is constructed of a flexible tube containing fiber optics and a miniature CCD
(or other type) camera and light located at the tube's distal end. A small lens is employed at the tube end in order to focus light onto the camera.
During a colonoscopy procedure, the distal end of a colonoscope is inserted into the colon and images of the interior walls of the colon are transmitted to a video screen. In this manner, abnormalities in the colon may be observed and, in certain instances, polyps identified and removed such as for biopsy. Because it is extremely important that the view of the colon walls not be impeded by waste matter, and because the size of the lens of the colonoscope is very small and therefore easily obstructed, it is critical to performing a successful colonoscopy that the colon be thoroughly cleansed prior to the procedure.
For the foregoing reasons, various colon preparation compositions and methods have been employed in the past for cleansing or purging the colon prior to endoscopy. Although many of these compositions and/or methods achieve their intended purpose, known colon preparation procedures are inconvenient and/or uncomfortable to the patient to which they are administered.' For example, a commonly used colon preparation composition is manufactured and sold under the tradename Fleet Phospho-Soda ~M (hereinafter FleetTM) . In order to achieve the desired result using FleetTM (sufficient cleansing of the colon), a patient must typically ingest approximately 80 ounces or more of fluids over a relatively short interval of time the day or evening prior to the colonoscopy procedure. Because the ingestion of large volumes of fluid can cause discomfort and, in some instances, nausea or other undesirable symptoms, alternative means to cleanse a colon prior to endoscopy are desired.
In view of the above-enumerated drawbacks, it is apparent that there exists a need in the art for compositions and/or methods for pre-colonoscopy colon preparation which overcome the above drawbacks. It is a purpose of this invention to fulfill these needs in the art, as well as other needs which will become apparent to the skilled artisan once given the above disclosure.
SUMMARY OF INVENTION
Generally speaking, this invention fulfills the above described needs in the art by providing:
a method of cleansing a colon in preparation for a colonoscopy comprising:
ingesting a combination of compositions in pharmaceutically effective amounts, said combination of compositions comprising: bisacodyl, metoclopramide, a phosphorus containing composition, and sodium.
In further embodiments, therein is provided:
a combination of compositions for cleansing a colon prior to a medical examination procedure, the combination of compositions comprising:
a pharmaceutically effective amount of metoclopramide;
a pharmaceutically effective amount of bisacodyl;
a pharmaceutically~effective amount of a phosphorus containing composit~ion~ and a pharmaceutically effective amount of sodium. .
In some embodiments, the combination of compositions is ingested in sequential doses over a multi-day time-period.
In still other embodiments, the sequential doses comprise: a first dose comprising bisacodyl; a second dose comprising a combination of bisacodyl, metoclopramide, a phosphorus containing composition, and sodium a third dose comprising bisacodyl, a phosphorus containing composition, and sodium and a fourth dose comprising metoclopramide.
In still further embodiments, the need for consuming large volumes of liquid prior to colonoscopy procedure is eliminated.
DETAILED DESCRTPTION OF CERTAIN EMBODIMENTS
For a more complete understanding of the present invention and advantages thereof, reference is now made to the following description of various illustrative and non-limiting embodiments.
In an exemplar embodiment of the subject invention, pharmaceutically effective amounts of a combination of pharmaceutical compositions are prescribed for oral consumption by a patient. In some preferred embodiments, the compositions are ingested as a series of sequential doses during a time interval of approximately 2-3 days.
Although the compositions are preferably administered in tablet or capsule form for ease of consumption, other forms of administration, in similar doses, are of course acceptable (e. g. sachets dissolved in water). It is noted in this regard, however, that one of the primary objectives of the instant invention is the elimination of the need for requiring the consumption of large volumes of liquid. For this reason, tablets or capsules are the most preferred method of administration.
The pharmaceutical compositions which are administered according to the method of the subject invention and/or comprise the combination according to the subject invention are as follows:
Compositions:
I. Common Name: Metoclopramide Chemical Name: (4-amino-5-chloro-N-[2 -(diethylamino) ethyl]-2-methoxy benzamide monohydrochloride monohydrate) Chemical Formula: ClqH2~C1N3O~, Available under the tradename: ReglanTM
II. Common Name: Bisacodyl Chemical Name: (4,4'-(2-pyridylmethylene) di(phenylacetate)) Chemical Formula : C2~H19NOQ
Available under the tradename: DulcolaxTM
III. Common Name: Phosphate or a phosphate containing composition such as (preferably) potassium phosphate, monobasic sodium phosphate, or dibasic sodium phosphate.
Chemical Formula: K~P04 (x = 1-3) is Available under the tradename: K-PhosTM or K-Phos-NeutralTM (also containing an appropriate dose ratio of sodium) IV. Common Name: Sodium Chemical Symbol: Na Contained, in the appropriate ratio relative to 2S phosphate, as an ingredient in K-PhosTM or K-Phos-NeutralTM.
In preferred embodiments, the compositions are administered according to the following example dosage amounts:
Dosages:
In further embodiments, therein is provided:
a combination of compositions for cleansing a colon prior to a medical examination procedure, the combination of compositions comprising:
a pharmaceutically effective amount of metoclopramide;
a pharmaceutically effective amount of bisacodyl;
a pharmaceutically~effective amount of a phosphorus containing composit~ion~ and a pharmaceutically effective amount of sodium. .
In some embodiments, the combination of compositions is ingested in sequential doses over a multi-day time-period.
In still other embodiments, the sequential doses comprise: a first dose comprising bisacodyl; a second dose comprising a combination of bisacodyl, metoclopramide, a phosphorus containing composition, and sodium a third dose comprising bisacodyl, a phosphorus containing composition, and sodium and a fourth dose comprising metoclopramide.
In still further embodiments, the need for consuming large volumes of liquid prior to colonoscopy procedure is eliminated.
DETAILED DESCRTPTION OF CERTAIN EMBODIMENTS
For a more complete understanding of the present invention and advantages thereof, reference is now made to the following description of various illustrative and non-limiting embodiments.
In an exemplar embodiment of the subject invention, pharmaceutically effective amounts of a combination of pharmaceutical compositions are prescribed for oral consumption by a patient. In some preferred embodiments, the compositions are ingested as a series of sequential doses during a time interval of approximately 2-3 days.
Although the compositions are preferably administered in tablet or capsule form for ease of consumption, other forms of administration, in similar doses, are of course acceptable (e. g. sachets dissolved in water). It is noted in this regard, however, that one of the primary objectives of the instant invention is the elimination of the need for requiring the consumption of large volumes of liquid. For this reason, tablets or capsules are the most preferred method of administration.
The pharmaceutical compositions which are administered according to the method of the subject invention and/or comprise the combination according to the subject invention are as follows:
Compositions:
I. Common Name: Metoclopramide Chemical Name: (4-amino-5-chloro-N-[2 -(diethylamino) ethyl]-2-methoxy benzamide monohydrochloride monohydrate) Chemical Formula: ClqH2~C1N3O~, Available under the tradename: ReglanTM
II. Common Name: Bisacodyl Chemical Name: (4,4'-(2-pyridylmethylene) di(phenylacetate)) Chemical Formula : C2~H19NOQ
Available under the tradename: DulcolaxTM
III. Common Name: Phosphate or a phosphate containing composition such as (preferably) potassium phosphate, monobasic sodium phosphate, or dibasic sodium phosphate.
Chemical Formula: K~P04 (x = 1-3) is Available under the tradename: K-PhosTM or K-Phos-NeutralTM (also containing an appropriate dose ratio of sodium) IV. Common Name: Sodium Chemical Symbol: Na Contained, in the appropriate ratio relative to 2S phosphate, as an ingredient in K-PhosTM or K-Phos-NeutralTM.
In preferred embodiments, the compositions are administered according to the following example dosage amounts:
Dosages:
Up to 30 mg of bisacodyl, preferably between 5-30 mg, more preferably between 10-30 mg, and most preferably between 20-30 mg.
Up to 30 mg of metoclopramide, preferably between 5-30 mg, more preferably between 10-30 mg, and most preferably between 20-30 mg.
Up to 3.6 g of potassium phosphate (preferably as K-Phos or K-Phos-Neutral which contains an approximate ratio of phosphate to potassium of 5:1), preferably between 600 mg and 3 g, more preferably between 1.2-3 g, and most preferably between 1.8-3 g.
Up to 3.6 g of sodium (e.g. contained in K-Phos or K-Phos-Neutral), preferably between 600 mg and 3 g, more preferably between 1.2-3 g, and most preferably between 1.8-3 g.
A preferred dosage schedule is set forth below. This schedule is normally provided to patients prior to a colonoscopy procedure and details the manner and amount of the doses as well as when they are to be taken. In this regard, the instructions below are intended for a patient with a procedure scheduled for the afternoon of the third day following the beginning of the cleansing program.
Different instructions may, of course, be provided for morning procedures, or variations in the instructions made for other reasons when necessary or simply as desired. The instructions below, however, have proven in practice to be particularly successful for the majority of patients.
Up to 30 mg of metoclopramide, preferably between 5-30 mg, more preferably between 10-30 mg, and most preferably between 20-30 mg.
Up to 3.6 g of potassium phosphate (preferably as K-Phos or K-Phos-Neutral which contains an approximate ratio of phosphate to potassium of 5:1), preferably between 600 mg and 3 g, more preferably between 1.2-3 g, and most preferably between 1.8-3 g.
Up to 3.6 g of sodium (e.g. contained in K-Phos or K-Phos-Neutral), preferably between 600 mg and 3 g, more preferably between 1.2-3 g, and most preferably between 1.8-3 g.
A preferred dosage schedule is set forth below. This schedule is normally provided to patients prior to a colonoscopy procedure and details the manner and amount of the doses as well as when they are to be taken. In this regard, the instructions below are intended for a patient with a procedure scheduled for the afternoon of the third day following the beginning of the cleansing program.
Different instructions may, of course, be provided for morning procedures, or variations in the instructions made for other reasons when necessary or simply as desired. The instructions below, however, have proven in practice to be particularly successful for the majority of patients.
PRE-COLONOSCOPY DOSAGE INSTRUCTIONS:
Two days prior to the procedure, the patient is directed to ingest 10 mg of bi.sacodyl (e. g. 2 DulcolaxTM
S tablets).
One day prior to the procedure, at approximately 8:00 AM, the patient is instructed to take 10 mg of metoclopramide (e. g. 1 ReglanTM tablet), 10 mg of bisacodyl (e. g. 2 DulcolaxTM tablets), and 1.2 g each of potassium phosphate and sodium (e. g. approximately 4 K-Phos-NeutralTM
tablets).
1S After the initial morning dosage, the patient is permitted to drink clear fluids up until three hours prior to the exam. Acceptable clear fluids are:
Water, strained fruit juices without pulp (apple, white grape, lemonade), clear broth or bouillon, coffee or tea (without milk or non-dairy creamer), and GatoradeTM, carbonated and non-carbonated soft drinks, Kool-AidTM or other fruit flavored drinks, plain Jell-OTM without added fruits or toppings, and 2S PopsiclesTM as long as none of the above are either red or purple.
At 12:00 Noon, the patient is directed to consume an additional 10 mg of bisacodyl and 1.2 g each of potassium phosphate and sodium (e. g. as commercially available tablets or capsules such as described above).
Two days prior to the procedure, the patient is directed to ingest 10 mg of bi.sacodyl (e. g. 2 DulcolaxTM
S tablets).
One day prior to the procedure, at approximately 8:00 AM, the patient is instructed to take 10 mg of metoclopramide (e. g. 1 ReglanTM tablet), 10 mg of bisacodyl (e. g. 2 DulcolaxTM tablets), and 1.2 g each of potassium phosphate and sodium (e. g. approximately 4 K-Phos-NeutralTM
tablets).
1S After the initial morning dosage, the patient is permitted to drink clear fluids up until three hours prior to the exam. Acceptable clear fluids are:
Water, strained fruit juices without pulp (apple, white grape, lemonade), clear broth or bouillon, coffee or tea (without milk or non-dairy creamer), and GatoradeTM, carbonated and non-carbonated soft drinks, Kool-AidTM or other fruit flavored drinks, plain Jell-OTM without added fruits or toppings, and 2S PopsiclesTM as long as none of the above are either red or purple.
At 12:00 Noon, the patient is directed to consume an additional 10 mg of bisacodyl and 1.2 g each of potassium phosphate and sodium (e. g. as commercially available tablets or capsules such as described above).
Note: The day prior to the colonoscopy procedure, the patient is advised not to take any fiber supplements or anti-inflammatories which are not approved in advance by the attending physician.
DAY 3: THE DAY OF THE PROCEDURE:
In the morning, the patient is instructed to take 10 mg of metoclopramide (e. g. 1 tablet of Reglan~').
The patient is permitted to continue to drink clear fluids until three hours prior to the procedure.
Note: Most normal medications are permitted to be taken but should be discussed first with the physician. If taken, they should be consumed with a small amount of water.
In the above instructions, the use of the term "day"
is intended only to represent an approximation of a recognized twenty-four hour time period (i.e. from midnight to midnight). Alternatively, the term "day" may be construed to mean the transition from one twenty-four~hour period to another or, further alternatively, a time period of approximately 18-30 hours. Eor these reasons, the times described herein should not be construed literally or limiting, because variations of these times may be employed to obtain acceptable results. Additionally, dosage amounts are provided only as particularly efficacious examples and should not be construed as restricting the scope of the invention. In this regard, patients having different physiologies and/or body weights will react differently to the various doses of the pharmaceutical compositions described herein and, therefore, the precise amounts that are prescribed thereof should be determined by the physician performing the procedure based on these as. well as other factors.
S When the above instructions are followed in practice, a cleansing of the colon takes place (e. g. by, in part, inducing peristalsis) which is adequate, in the majority of cases, for a successful colonoscopy to be performed. In this regard, the conditions required for performing a "successful colonoscopy" are defined as cleansing the colon sufficiently such that the interior colon walls may be clearly viewed for accurate diagnosis and such that the camera lens of the colonoscope is not significantly obstructed by food waste matter.
As will be noticed from the foregoing example, throughout a typical dosage schedule, only approximately 14 tablets (or capsules) are required to be ingested..
Surprisingly, however, consuming this relatively small number of pills is sufficient to obtain the cleansing necessary to permit successful colonoscopy. In contrast, some prior art colon preparation procedures dictate that upwards of forty pills be consumed over a similar time period. Moreover, the inventive combination of compositions and method for administration thereof does not require that unusual and/or uncomfortable or nauseating volumes of liquids be consumed. For these reasons, the above-enumerated drawbacks of the prior art are avoided.
Once given the above disclosure, many other features, modifications, and improvements will become apparent to the slcilled artisan. Such other features, modifications, and improvements are therefore considered to be part of this invention, the scope of which is to be determined by the following claims:
DAY 3: THE DAY OF THE PROCEDURE:
In the morning, the patient is instructed to take 10 mg of metoclopramide (e. g. 1 tablet of Reglan~').
The patient is permitted to continue to drink clear fluids until three hours prior to the procedure.
Note: Most normal medications are permitted to be taken but should be discussed first with the physician. If taken, they should be consumed with a small amount of water.
In the above instructions, the use of the term "day"
is intended only to represent an approximation of a recognized twenty-four hour time period (i.e. from midnight to midnight). Alternatively, the term "day" may be construed to mean the transition from one twenty-four~hour period to another or, further alternatively, a time period of approximately 18-30 hours. Eor these reasons, the times described herein should not be construed literally or limiting, because variations of these times may be employed to obtain acceptable results. Additionally, dosage amounts are provided only as particularly efficacious examples and should not be construed as restricting the scope of the invention. In this regard, patients having different physiologies and/or body weights will react differently to the various doses of the pharmaceutical compositions described herein and, therefore, the precise amounts that are prescribed thereof should be determined by the physician performing the procedure based on these as. well as other factors.
S When the above instructions are followed in practice, a cleansing of the colon takes place (e. g. by, in part, inducing peristalsis) which is adequate, in the majority of cases, for a successful colonoscopy to be performed. In this regard, the conditions required for performing a "successful colonoscopy" are defined as cleansing the colon sufficiently such that the interior colon walls may be clearly viewed for accurate diagnosis and such that the camera lens of the colonoscope is not significantly obstructed by food waste matter.
As will be noticed from the foregoing example, throughout a typical dosage schedule, only approximately 14 tablets (or capsules) are required to be ingested..
Surprisingly, however, consuming this relatively small number of pills is sufficient to obtain the cleansing necessary to permit successful colonoscopy. In contrast, some prior art colon preparation procedures dictate that upwards of forty pills be consumed over a similar time period. Moreover, the inventive combination of compositions and method for administration thereof does not require that unusual and/or uncomfortable or nauseating volumes of liquids be consumed. For these reasons, the above-enumerated drawbacks of the prior art are avoided.
Once given the above disclosure, many other features, modifications, and improvements will become apparent to the slcilled artisan. Such other features, modifications, and improvements are therefore considered to be part of this invention, the scope of which is to be determined by the following claims:
Claims (16)
1. A method of cleansing a colon in preparation for a colonoscopy comprising:
ingesting a combination of compositions in pharmaceutically effective amounts, said combination of compositions comprising: bisacodyl, metoclopramide, a phosphorus containing composition, and sodium.
ingesting a combination of compositions in pharmaceutically effective amounts, said combination of compositions comprising: bisacodyl, metoclopramide, a phosphorus containing composition, and sodium.
2. The method according to claim 1 wherein said combination of compositions, when ingested by a patient having a colon, is sufficient to trigger a physiological response, including peristalsis of the colon, whereby the colon is subsequently adequately cleansed for a colonoscopy procedure.
3. The method according to claim 2 wherein said phosphorus containing composition is selected from the group comprising: phosphate, potassium phosphate, monobasic sodium phosphate, and dibasic sodium phosphate.
4. The method according to claim 3 wherein said combination of compositions is ingested in a series of sequential doses comprising:
a) a first dose comprising bisacodyl;
b) a second dose comprising a combination of bisacodyl, metoclopramide, said phosphorus containing composition, and sodium;
c) a third dose comprising bisacodyl, said phosphorus containing composition, and sodium and d) a fourth dose comprising metoclopramide.
a) a first dose comprising bisacodyl;
b) a second dose comprising a combination of bisacodyl, metoclopramide, said phosphorus containing composition, and sodium;
c) a third dose comprising bisacodyl, said phosphorus containing composition, and sodium and d) a fourth dose comprising metoclopramide.
5. The method according to claim 4 wherein said second dose is ingested approximately 8-36 hours after said first dose.
6. The method according to claim 5 wherein said third dose is ingested approximately 2-14 hours after said second dose.
7. The method according to claim 6 wherein said fourth dose is ingested approximately 6-14 hours after said third dose.
8. The method according to claim 5 wherein said first dose is ingested approximately two days prior to a colonoscopy procedure.
9. The method according to claim 8 wherein:
a) said first dose comprises 5-15 mg bisacodyl;
b) said second dose comprises a combination of 5-15 mg bisacodyl, 5-15 mg metoclopramide, .5-2 g of said phosphorus containing composition, and .5-2g sodium;
c) said third dose comprises 5-15 mg bisacodyl, .5-2 g of said phosphorus containing composition, and .5-2 g sodium; and d) said fourth dose comprises 5-15 mg metoclopramide.
a) said first dose comprises 5-15 mg bisacodyl;
b) said second dose comprises a combination of 5-15 mg bisacodyl, 5-15 mg metoclopramide, .5-2 g of said phosphorus containing composition, and .5-2g sodium;
c) said third dose comprises 5-15 mg bisacodyl, .5-2 g of said phosphorus containing composition, and .5-2 g sodium; and d) said fourth dose comprises 5-15 mg metoclopramide.
10. A combination of compositions for cleansing a colon prior to a medical examination procedure, said combination of compositions comprising:
a pharmaceutically effective amount of metoclopramide;
a pharmaceutically effective amount of bisacodyl;
a pharmaceutically effective amount of a phosphorus containing composition: and a pharmaceutically effective amount of sodium.
a pharmaceutically effective amount of metoclopramide;
a pharmaceutically effective amount of bisacodyl;
a pharmaceutically effective amount of a phosphorus containing composition: and a pharmaceutically effective amount of sodium.
11. The combination of compositions according to claim 10 wherein said combination of compositions, when ingested by a patient having a colon, is sufficient to trigger a physiological response, including peristalsis of the colon, whereby the colon is subsequently adequately cleansed for a colonoscopy procedure.
12. The combination of compositions according to claim 11 wherein said phosphorus containing composition is selected from the group comprising: phosphate, potassium phosphate, monobasic sodium phosphate, and dibasic sodium phosphate.
13. The combination of compositions according to claim 12 wherein said combination comprises a series of sequential doses comprising:
a) a first dose comprising bisacodyl;
b) a second dose comprising a combination of bisacodyl, metoclopramide, said phosphorus containing composition, and sodium;
c) a third dose comprising bisacodyl, said phosphorus containing composition, and sodium; and d) a fourth dose comprising metoclopramide.
a) a first dose comprising bisacodyl;
b) a second dose comprising a combination of bisacodyl, metoclopramide, said phosphorus containing composition, and sodium;
c) a third dose comprising bisacodyl, said phosphorus containing composition, and sodium; and d) a fourth dose comprising metoclopramide.
14. The combination of compositions according to claim 13 wherein:
a) said first dose comprises 5-15 mg bisacodyl;
b) said second dose comprises a combination of 5-15 mg bisacodyl, 5-15 mg metoclopramide, .5-2 g of said phosphorus containing composition, and .5-2 g of sodium;
c) said third dose comprises 5-15 mg bisacodyl, .5-2 g of said phosphorus containing composition, and .5-2 g sodium and d) said fourth dose comprises 5-15 mg metoclopramide.
a) said first dose comprises 5-15 mg bisacodyl;
b) said second dose comprises a combination of 5-15 mg bisacodyl, 5-15 mg metoclopramide, .5-2 g of said phosphorus containing composition, and .5-2 g of sodium;
c) said third dose comprises 5-15 mg bisacodyl, .5-2 g of said phosphorus containing composition, and .5-2 g sodium and d) said fourth dose comprises 5-15 mg metoclopramide.
15. The combination of compositions according to claim 14 wherein said metoclopramide is defined by the formula C14H22ClN3O2.
16. The combination of compositions according to claim 15 wherein said bisacodyl is defined by the formula C22H19NO4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/668,071 US7049319B2 (en) | 2003-09-23 | 2003-09-23 | Colon cleansing composition and method |
| US10/668,071 | 2003-09-23 | ||
| PCT/US2004/028215 WO2005034728A2 (en) | 2003-09-23 | 2004-08-31 | Colon cleansing composition and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2540147A1 true CA2540147A1 (en) | 2005-04-21 |
Family
ID=34313425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002540147A Abandoned CA2540147A1 (en) | 2003-09-23 | 2004-08-31 | Colon cleansing composition and method |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US7049319B2 (en) |
| EP (1) | EP1701723A4 (en) |
| CA (1) | CA2540147A1 (en) |
| WO (1) | WO2005034728A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7049319B2 (en) * | 2003-09-23 | 2006-05-23 | Semaan Abboud | Colon cleansing composition and method |
| DE102005041711A1 (en) * | 2005-09-01 | 2007-03-08 | Kappstein, Ines, Prof. Dr.med. | Intestine-rinsing solution, useful to clean the intestine before intestine reflux and before operations, comprises a bouillon/broth and a salt concentrate for taste |
| CA2725125A1 (en) * | 2008-05-23 | 2009-11-26 | Kingston General Hospital | Colon cleansing method and kit |
| US20100178360A1 (en) | 2009-01-13 | 2010-07-15 | Universite Libre De Bruxelles | Nutritive composition |
| RU2651751C2 (en) | 2011-01-28 | 2018-04-23 | Уильям А. ШЕЙВЕР | Method, composition and package for bowel cleansing |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US39400A (en) * | 1863-08-04 | Improvement in lamp-burners | ||
| US22933A (en) * | 1859-02-15 | Stove | ||
| US85990A (en) * | 1869-01-19 | Levi branson | ||
| US20025A (en) * | 1858-04-20 | Churn | ||
| US45153A (en) * | 1864-11-22 | Improvement in oil-ejectors for oil-wells | ||
| US4403982A (en) * | 1978-08-28 | 1983-09-13 | Clayton Ralph S | Colon cleansing system and technique |
| US4406655A (en) * | 1978-08-28 | 1983-09-27 | Clayton Ralph S | Colon cleansing system and technique |
| IL86859A (en) * | 1987-07-10 | 1991-12-15 | E Z Em Inc | Aqueous cathartic solution containing inorganic salts |
| US5219573A (en) * | 1989-10-17 | 1993-06-15 | Hershey Foods Corporation | L-sugar laxatives |
| US5197950A (en) * | 1990-07-20 | 1993-03-30 | Clayton Ralph S | Scheduled bowel management system |
| US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
| US6103268A (en) * | 1995-11-03 | 2000-08-15 | Borody; Thomas Julius | Administering osmotic colonic evacuant containing a picosulfate |
| AUPN634595A0 (en) * | 1995-11-03 | 1995-11-30 | Borody, Thomas Julius | Improved method for colonic evacuation |
| DK0858326T3 (en) * | 1996-05-08 | 2003-07-07 | Craig A Aronchick | Non-aqueous colon laxatives |
| US6331116B1 (en) | 1996-09-16 | 2001-12-18 | The Research Foundation Of State University Of New York | System and method for performing a three-dimensional virtual segmentation and examination |
| US5997906A (en) * | 1996-11-13 | 1999-12-07 | C.B. Fleet Company, Inc. | Coated sodium phosphate bowel cleanser |
| US6162464A (en) * | 1997-03-31 | 2000-12-19 | Inkine Pharmaceutical, Inc. | Non-aqueous colonic purgative formulations |
| KR100529512B1 (en) * | 1997-04-18 | 2005-11-22 | 얀센 파마슈티카 엔.브이. | Use of 5HT3 antagonists for promoting intestinal lavage |
| US6447763B1 (en) * | 1998-06-12 | 2002-09-10 | Ian L. Gordon | Method and system for production and collection of lavage induced stool (LIS) for chemical and biologic tests of cells |
| US6444198B1 (en) * | 1999-02-22 | 2002-09-03 | Smithkline Beecham Corporation | Effervescent laxatives |
| US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| DE60225266T2 (en) | 2001-05-18 | 2009-03-19 | Sucampo Ag | COMPOSITION WITH INDUCTIVE CATHARTIC EFFECT |
| US7049319B2 (en) * | 2003-09-23 | 2006-05-23 | Semaan Abboud | Colon cleansing composition and method |
-
2003
- 2003-09-23 US US10/668,071 patent/US7049319B2/en not_active Expired - Fee Related
-
2004
- 2004-08-31 WO PCT/US2004/028215 patent/WO2005034728A2/en active Application Filing
- 2004-08-31 CA CA002540147A patent/CA2540147A1/en not_active Abandoned
- 2004-08-31 EP EP04782649A patent/EP1701723A4/en not_active Ceased
-
2005
- 2005-11-23 US US11/284,842 patent/US7335664B2/en not_active Expired - Fee Related
-
2008
- 2008-02-06 US US12/026,606 patent/US20080220087A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080220087A1 (en) | 2008-09-11 |
| WO2005034728A3 (en) | 2005-10-27 |
| EP1701723A4 (en) | 2007-05-09 |
| US7049319B2 (en) | 2006-05-23 |
| EP1701723A2 (en) | 2006-09-20 |
| WO2005034728A2 (en) | 2005-04-21 |
| US7335664B2 (en) | 2008-02-26 |
| US20060073214A1 (en) | 2006-04-06 |
| US20050064043A1 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6132767A (en) | Administering osmotic colonic evacuant containing a picosulfate | |
| US6103268A (en) | Administering osmotic colonic evacuant containing a picosulfate | |
| US7335664B2 (en) | Colon cleansing composition and method | |
| CN103391790A (en) | Method, composition and package for bowel cleansing | |
| JP6297334B2 (en) | Colonoscopy pretreatment | |
| US20040191213A1 (en) | Method of bowel cleansing | |
| EP2322190A1 (en) | Compositions for bowel cleansing and use thereof | |
| Ozer et al. | Endoscopic extraction of living fasciola hepatica: case report and literature review | |
| US9375441B2 (en) | Lactulose for bowel evacuation | |
| EP2281562A2 (en) | Method of bowel cleansing | |
| Breitenbach | ‘Halloween diarrhea’ An unexpected trick of sorbitol-containing candy | |
| MX2011009987A (en) | Compositions for bowel preparation and methods of use thereof. | |
| CN111184867A (en) | Chemical medicine composition for treating helicobacter pylori infection | |
| Hutchinson et al. | A PROSEPECTIVE STUDY ASSESSING THE COMPLICATIONS ASSOCIATED WITH THE USE OF WIRELESS-CAPSULE ENDOSCOPY (WCE): 871 | |
| US20220249542A1 (en) | Bowel cleansing chemical composition and associated use therefore | |
| US11298373B1 (en) | Bowel cleansing chemical composition and associated use therefore | |
| Siboulet et al. | A New “One-Minute” Treatment of Gonorrhoea | |
| US20210177815A1 (en) | Colonoscopy preparation enhancer | |
| Eliakim et al. | Diffuse intramural esophageal pseudodiverticulosis. | |
| Cittadini et al. | A simple, innocuous and effective method for cleansing the large bowel without enemas | |
| US20200352855A1 (en) | Colon Cleansing Composition and Methods of Using Same | |
| Hussein | Surgical Management of Cholelithiasis Cross-sectional study of 41 patients | |
| Farmer et al. | The absorption of vitamin C (l-ascorbic acid) from the intestinal tract, in health and disease | |
| US20120214764A1 (en) | Method and kit for gastro-intestinal cleansing | |
| JP2011157383A (en) | Method for lavaging intestine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |